By Metro US
Posted on
TOKYO (Reuters) – Fujitsu Ltd, Mizuho Financial Group Inc, and drugmaker PeptiDream Inc said on Thursday they are forming a joint venture to develop treatments for COVID-19.
The new company, to be called PeptiAID Inc, will research and develop peptide therapeutics for the current SARS-CoV-2 virus and potential future coronavirus outbreaks, the companies said in a release.
The joint venture also includes Takenaka Corp and Kishida Chemical Co.
(Reporting by Rocky Swift; Editing by Kim Coghill)
Mario Andretti offended by F1 rejection. ‘If they want want blood, well, I’m ready,’ says 1978 champ
Coyotes’ move to Salt Lake City elicits opposing responses in 2 cities
Buffalo Bills owner Terry Pegula explores selling non-controlling, minority stake in franchise
Sign of the times: NCAA approves coach-to-player helmet communication for 2024 football season
Semyon Varlamov to start Game 1 for Islanders vs. Hurricanes
Mayor Adams restores $500 million for education, leaves open-ended questions about free child care in NYC
Here’s how Phish is using the Sphere’s technology to give fans something completely different
Police to review security outside courthouse hosting Trump’s trial after man sets himself on fire
Top women honored at Schneps Media Power Women of Manhattan
Housing Works cuts ribbon at new Harlem site and expands Food is Medicine program with $300,000 check
BNSF Railway says it didn’t know about asbestos that’s killed hundreds in Montana town
Soldiers who lost limbs in Gaza fighting are finding healing on Israel’s amputee soccer team
Nevada Supreme Court rulings hand setbacks to gun-right defenders and anti-abortion activists
As syphilis cases among US newborns soar, doctors group advises more screening during pregnancy
